Rescue events included: Participants with worsening sarcoidosis requiring rescue treatment; and participants failing to follow protocol defined concomitant sarcoidosis medication requirements (oral corticosteroids [OCS] taper/immunosuppressive therapy [IST] removal/prohibited medication). Participants with premature treatment discontinuation in the DB period without rescue event were considered as with missing rescue event status and excluded from analysis.

mITT population included all randomized participants who received any amount of DB study treatment, excluding participants with a quality event. 'Overall number of participants analyzed' = participants with rescue event status.

FVC is the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Percent of predicted FVC = (actual FVC measurement)/(predicted value of FVC) * 100. Least square (LS) mean and standard error (SE) were calculated using mixed model for repeated measure (MMRM).

The mITT population included all randomized participants who received any amount of DB study treatment, excluding participants with a quality event. 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

Time of first rescue event was defined as the time from randomization to the rescue event date. Rescue events included: Participants with worsening sarcoidosis requiring rescue treatment; and participants failing to follow protocol defined concomitant sarcoidosis medication requirements (OCS taper/IST removal/prohibited medication). Data was calculated using the Kaplan-Meier estimator.

mITT population included all randomized participants who received any amount of DB study treatment, excluding participants with a quality event.

Percentage of participants achieving OCS taper (achieving OCS dose ≤5 milligrams [mg] at end of Week 10 [Day 77] for participants with baseline OCS >10 mg/day, achieving ≤ 5 mg at end of Week 6 [Day 49] for participants with baseline OCS >5 to ≤10 mg/day) without any rescue event during the DB period for participants with OCS >5 mg/day at baseline are reported.

The mITT population included all randomized participants who received any amount of DB study treatment, excluding participants with a quality event. 'Overall number of participants analyzed' = participants with OCS >5 mg/day at baseline.

The KSQ has 29 questions (items 1 to 16, and items 26-38). The KSQ Lung domain score was calculated based on items 11 to 16. Each item was answered on a 7-point scale where 1 means the participant experienced symptoms all the time and 7 means the participant did not experience the symptom at all. The raw item scores were first converted into item re-scores using the first conversion step. Then, the re-scores for the 6 items were totaled and the total converted into the logit 1 (worst symptom) - 100 (no symptom) score, where higher score indicating better health. LS mean and SE were calculated using MMRM.

The mITT population included all randomized participants who received any amount of DB study treatment, excluding participants with a quality event. 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

An adverse event (AE) was any untoward medical occurrence in a participant administered the study drug and which did not necessarily have a causal relationship with this treatment. TEAEs are those AEs with start date on or after the start date of treatment through the earlier of 18-week post last dose during DB period or prior to first dose during OLE period, whichever was earlier. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Safety population included all randomized participants who received any amount of study treatment.